Analyst Upgrades – Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Gets Upgraded By William Blair from Market Perform to Outperform

ME Staff
-
0

Analyst Ratings For Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Today, Arrowhead Pharmaceuticals (NASDAQ:ARWR) stock received an upgrade by William Blair from Market Perform to Outperform.

There are 4 hold ratings, 1 buy rating on the stock.

The current consensus rating on Arrowhead Pharmaceuticals (NASDAQ:ARWR) is Hold (Score: 2.20) with a consensus target price of $2.00 per share, a potential 39.58% downside.

Some recent analyst ratings include

  • 9/18/2017-William Blair Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 9/13/2017-Chardan Capital Reiterated Rating of Neutral.
  • 9/15/2017-Cantor Fitzgerald Reiterated Rating of Hold.
  • 8/4/2017-Jefferies Group LLC Reiterated Rating of Hold.
  • 7/28/2017-Piper Jaffray Companies Reiterated Rating of Hold.

Recent Insider Trading Activity For Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has insider ownership of 4.57% and institutional ownership of 20.61%.

  • On 10/14/2016 Douglas B. Given, Director, sold 12,000 with an average share price of $6.72 per share and the total transaction amounting to $80,640.00. View SEC Filing
  • On 8/23/2016 Kenneth Allen Myszkowski, CFO, sold 6,900 with an average share price of $8.00 per share and the total transaction amounting to $55,200.00. View SEC Filing
  • On 8/22/2016 Kenneth Allen Myszkowski, CFO, sold 13,100 with an average share price of $8.00 per share and the total transaction amounting to $104,800.00. View SEC Filing
  • On 12/30/2015 Kenneth Allen Myszkowski, CFO, sold 23,347 with an average share price of $6.13 per share and the total transaction amounting to $143,117.11. View SEC Filing
  • On 10/28/2015 Mauro Ferrari, Director, bought 400 with an average share price of $7.62 per share and the total transaction amounting to $3,048.00. View SEC Filing
  • On 10/9/2015 Mauro Ferrari, Director, bought 1,900 with an average share price of $6.19 per share and the total transaction amounting to $11,761.00. View SEC Filing
  • On 1/5/2015 David L Lewis, Insider, sold 15,000 with an average share price of $8.01 per share and the total transaction amounting to $120,150.00. View SEC Filing

Recent Trading Activity for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Shares of Arrowhead Pharmaceuticals closed the previous trading session at with shares trading hands.